| h-a8165b3b | Complement-Mediated Synaptic Pruning Dysregulation | 0.61 | 0.50 | C1QA | proposed | 2026-04-03 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-509c8f986c | Cell-state stratification is required to resolve Biophysical Determinants Shifti | 0.61 | 0.58 | TDP-43 | proposed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-3941ee023b | Cell-state stratification is required to resolve Cell-Autonomous vs Non-Cell-Aut | 0.61 | 0.58 | FUS- | proposed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| h-060fcd7297 | Cell-state stratification is required to resolve Non-Neuronal Transcriptional Ch | 0.61 | 0.58 | APOE | proposed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| h-ccf142ff65 | Cell-state stratification is required to resolve m6A RNA Modification and Alpha- | 0.61 | 0.58 | RNA | proposed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-53a96467cb | Cell-state stratification is required to resolve CCL2-CCR2 Axis at NMJ: Mechanis | 0.61 | 0.58 | NMJ | proposed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| h-879492865f | Cell-state stratification is required to resolve Causal Sequence of TDP-43 Nucle | 0.61 | 0.58 | ALS | proposed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| h-2352580bf5 | Cell-state stratification is required to resolve Genetic Aging Landscape Variant | 0.61 | 0.58 | | proposed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| h-14362edf60 | Cell-state stratification is required to resolve Proteogenomic Network Hubs as D | 0.61 | 0.58 | | proposed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| h-d92beb28e8 | Cell-state stratification is required to resolve VEGF Family GWAS Signals and Ce | 0.61 | 0.58 | GWAS | proposed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| h-5779a65ad4 | Cell-state stratification is required to resolve DPP6 GWAS Signal: Cell-Type Reg | 0.61 | 0.58 | GWAS | proposed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| h-5d6faf1d9e | Cell-state stratification is required to resolve Sex-Specific Microglial States | 0.61 | 0.58 | | proposed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |
| hyp_test_c201b8c0 | Test: TREM2 enhances amyloid clearance | 0.61 | 0.27 | TREM2 | proposed | 2026-04-17 | test-hypothesis-fixtures-v1 |
| h-494861d2 | Synaptic Pruning Precision Therapy | 0.61 | 0.70 | C1QA, C3, CX3CR1, CX3CL1 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-62c78d8b | CaMKII-Dependent Synaptic Circuit Amplification | 0.61 | 0.65 | CAMK2A | proposed | 2026-04-04 | SDA-2026-04-03-26abc5e5f9f2 |
| h-f1f1b53e9e | HDAC3-Dependent A1 Astrocyte Commitment Window | 0.61 | 0.65 | HDAC3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| h-29ef94d5 | Epigenetic Memory Reprogramming for Alzheimer's Disease | 0.61 | 0.50 | BDNF, CREB1, synaptic plasticity genes | proposed | 2026-04-03 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| h-69bde12f | APOE4-Lipid Metabolism Correction | 0.61 | 0.40 | APOE | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-ab836ca0c7 | TREM2-SYK microglial activation as a stage-specific Alzheimer's disease modifier | 0.61 | 0.72 | TREM2; SYK | proposed | 2026-04-29 | SDA-2026-04-29-gap-test-20260425-224949 |
| h-8a16a3f363 | NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression | 0.61 | 0.65 | NLRP3 | proposed | 2026-04-28 | SDA-TEST-PREREG-003 |
| h-13ea09f59f | Basal forebrain NGF/TrkA trophic failure is an upstream trigger that makes choli | 0.61 | 0.65 | NGF, NTRK1, APP | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-e849205bca |
| h-55bc3e94f8 | C1q effector output is determined more by binding partner identity than by subce | 0.61 | 0.58 | C1QA,C1QB,C1QC,NPTX1,NPTX2,APP,C3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| h-6b814d561d | The most realistic translational use of physiological SCFAs is as an adjunct to | 0.61 | 0.49 | GLP1R/NLRP3 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-18cce7b525 |
| h-7533f6ac3b | Female microglia exhibit heightened complement gene expression and pruning capac | 0.61 | 0.68 | ESR2 (NR3A2), KDM6A (UTX), C1QA, C1QB, NFKB1 | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-4805632af8 | H2: Perforant Path Synapse Loss via Early Complement Cascade Activation | 0.61 | 0.62 | C1QA, C1QB, C3, ITGAM | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-753ee7a30b | APOE4 preferentially signals through LRP1 over LDLR, altering endosomal choleste | 0.61 | 0.62 | LRP1, NPC1, CTSD | proposed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |
| h-a98c87836b | Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway | 0.61 | 0.62 | PDGRIP1L (ALIX) | proposed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| h-4c4e39230f | H2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive | 0.61 | 0.68 | SUV39H1, CBX5 (HP1α), H3K9me3 mark | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| h-80b5226d73 | ALS-Associated G3BP1 Mutations Shift Phase Separation Equilibrium Toward Aberran | 0.61 | 0.70 | G3BP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-42f8fa19eb | Age-Accelerated miR-155 Upregulation Primes Nigral Microglia for Parkinson's Dis | 0.61 | 0.68 | miR-155 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4 |
| h-0ed345d73f | H1: Senolytic Clearance of Senescent APOE4 Astrocytes | 0.61 | 0.68 | CDKN2A (p16Ink4a) | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| h-ca624bf065 | Astrocyte LRP1-mediated tau uptake and APOE4-dependent secretion creates regiona | 0.61 | 0.63 | LRP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062052-946439a8 |
| h-c157796b69 | Tau Cross-Seeding and Interaction | 0.61 | 0.68 | MAPT | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a |
| h-6d411c20 | GDNF Gradient Establishment by Schwann Cells Enables Motor Re-innervation | 0.61 | 0.75 | GDNF | promoted | 2026-04-14 | SDA-2026-04-14-gap-pubmed-20260410-181356-57d1f917 |
| h-32b2bb56c8 | Aberrant Galectin-3 Expression on Stressed Synapses Creates Bridging Molecules | 0.61 | 0.60 | LGALS3 (Galectin-3) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-0b67a9f249 | Microglial priming is primarily epigenetic, with metabolic changes acting as cou | 0.61 | 0.58 | KDM6B | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |
| h-96772461 | Ketone-Based Metabolic Switching to Restore PV Interneuron Function | 0.61 | 0.62 | SIRT3, PVALB | promoted | 2026-04-17 | SDA-2026-04-16-gap-20260416-133111 |
| h-1775578a | Temporal TFEB Modulation Therapy | 0.61 | 0.30 | TFEB | proposed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-4b517512 | The Glial Ketone Metabolic Shunt Hypothesis | 0.61 | 0.50 | HMGCS2 | proposed | 2026-04-03 | SDA-2026-04-02-gap-v2-5d0e3052 |
| h-c34258ddeb | Perturbation-first validation should precede therapeutic claims for Biophysical | 0.61 | 0.55 | RNA | proposed | 2026-04-28 | 52661eaf-79f8-4647-8f48-3389f5af4d59 |
| h-1f3f0de239 | Perturbation-first validation should precede therapeutic claims for Cell-Autonom | 0.61 | 0.55 | ALS | proposed | 2026-04-28 | 687fb884-6d31-47c3-a83f-074bad980db6 |
| h-fe626fcf62 | Perturbation-first validation should precede therapeutic claims for Non-Neuronal | 0.61 | 0.55 | | proposed | 2026-04-28 | db9a224d-3ebb-429c-8f02-b703d71ca211 |
| h-0d597b942f | Perturbation-first validation should precede therapeutic claims for m6A RNA Modi | 0.61 | 0.55 | N6- | proposed | 2026-04-28 | b7f886d9-da3f-4e0d-a8a8-9c262e268796 |
| h-f9c6fa7676 | Perturbation-first validation should precede therapeutic claims for CCL2-CCR2 Ax | 0.61 | 0.55 | ALS | proposed | 2026-04-28 | f7f8019f-08f6-428b-adff-85e8ea202b60 |
| h-84566f4d8e | Perturbation-first validation should precede therapeutic claims for Causal Seque | 0.61 | 0.55 | | proposed | 2026-04-28 | 0ed3c364-07fd-4620-8e90-8bd33c14e370 |
| h-3b6e6d44d5 | Perturbation-first validation should precede therapeutic claims for Genetic Agin | 0.61 | 0.55 | | proposed | 2026-04-28 | bf5094c7-8ae0-4331-9871-d6f3078387c5 |
| h-9b0771a001 | Perturbation-first validation should precede therapeutic claims for Proteogenomi | 0.61 | 0.55 | | proposed | 2026-04-28 | 8ec36980-febb-4093-a5a1-387ea5768480 |
| h-e128d575e8 | Perturbation-first validation should precede therapeutic claims for VEGF Family | 0.61 | 0.55 | VEGF- | proposed | 2026-04-28 | a7f528aa-20c4-409d-a8c3-e2662850e63d |
| h-532333955e | Perturbation-first validation should precede therapeutic claims for DPP6 GWAS Si | 0.61 | 0.55 | | proposed | 2026-04-28 | 457c5bc3-21d8-42a3-bb99-b0fc6f3f9554 |
| h-3b12dd77de | Perturbation-first validation should precede therapeutic claims for Sex-Specific | 0.61 | 0.55 | | proposed | 2026-04-28 | dfb32151-9c40-452d-8063-0c57bae5c3d6 |